{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:04:30Z","timestamp":1787321070508,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ctro.2024.100790","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T22:18:18Z","timestamp":1714774698000},"page":"100790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-8842","authenticated-orcid":false,"given":"Sebastian H.","family":"Maier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-8960","authenticated-orcid":false,"given":"Stephan","family":"Sch\u00f6necker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8438-2758","authenticated-orcid":false,"given":"Vasiliki","family":"Anagnostatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Garny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8620-2305","authenticated-orcid":false,"given":"Alexander","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3627-7370","authenticated-orcid":false,"given":"Detlef","family":"Imhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-5089","authenticated-orcid":false,"given":"Clemens","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"K\u00f6lbl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Haussmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Budach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-1367","authenticated-orcid":false,"given":"Klaus-Henning","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9214-919X","authenticated-orcid":false,"given":"Elgin","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-8438","authenticated-orcid":false,"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1114-2771","authenticated-orcid":false,"given":"Raphael","family":"Bodensohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100790_b0005","article-title":"Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)","volume":"45","author":"Bodensohn","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2024.100790_b0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ijrobp.2008.05.034","article-title":"Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03","volume":"73","author":"Tsien","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1078-0432.CCR-11-2073","article-title":"Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma","volume":"18","author":"Tsien","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctro.2024.100790_b0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2014.07.014","article-title":"Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide","volume":"90","author":"Badiyan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2024.100790_b0025","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","article-title":"Initial results of a phase 2 trial of (18)F-DOPA PET-guided dose-escalated radiation therapy for glioblastoma","volume":"110","author":"Laack","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"14","key":"10.1016\/j.ctro.2024.100790_b0030","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1158\/1078-0432.CCR-22-0171","article-title":"Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma","volume":"28","author":"Harat","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctro.2024.100790_b0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2019.06.009","article-title":"Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma","volume":"138","author":"Fleischmann","year":"2019","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2024.100790_b0040","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2008.18.6437","article-title":"Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98","volume":"27","author":"Carrie","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2012.08.008","article-title":"QA makes a clinical trial stronger: evidence-based medicine in radiation therapy","volume":"105","author":"Weber","year":"2012","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2024.100790_b0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jnci\/djt001","article-title":"Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials","volume":"105","author":"Ohri","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/neuonc\/noad119","article-title":"Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)","volume":"26","author":"Laprie","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5317-x","article-title":"Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging","volume":"19","author":"Laprie","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctro.2024.100790_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2024.100790_b0070","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2017.12.013","article-title":"American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology","volume":"100","author":"Mayo","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1118\/1.598063","article-title":"Reporting and analyzing dose distributions: a concept of equivalent uniform dose","volume":"24","author":"Niemierko","year":"1997","journal-title":"Med Phys"},{"issue":"4","key":"10.1016\/j.ctro.2024.100790_b0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00066-011-0055-2","article-title":"Radiation treatment parameters for re-irradiation of malignant glioma","volume":"188","author":"Niyazi","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctro.2024.100790_b0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/1748-717X-8-287","article-title":"Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma","volume":"8","author":"Niyazi","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100790_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-014-0276-5","article-title":"Hippocampal EUD in primarily irradiated glioblastoma patients","volume":"9","author":"Bodensohn","year":"2014","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2024.100790_b0095","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s10147-015-0941-1","article-title":"A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients","volume":"21","author":"Bodensohn","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100790_b0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.radonc.2019.09.008","article-title":"Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model","volume":"142","author":"Niyazi","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2020.08.058","article-title":"Brain necrosis in adult patients after proton therapy: is there evidence for dependency on linear energy transfer?","volume":"109","author":"Niemierko","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100790_b0110","series-title":"Proceedings of the XVI\u2019th International Conference on the use of Computers in Radiotherapy (ICCR), Amsterdam, Netherlands","article-title":"Plastimatch: an open source software suite for radiotherapy image processing","author":"Sharp","year":"2010"},{"key":"10.1016\/j.ctro.2024.100790_b0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12880-015-0068-x","article-title":"Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool","volume":"15","author":"Taha","year":"2015","journal-title":"BMC Med Imaging"},{"issue":"Suppl 2","key":"10.1016\/j.ctro.2024.100790_b0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jmrs.618","article-title":"Clinical evaluation of deep learning and atlas-based auto-segmentation for critical organs at risk in radiation therapy","volume":"70","author":"Gibbons","year":"2023","journal-title":"J Med Radiat Sci"},{"issue":"Suppl 1","key":"10.1016\/j.ctro.2024.100790_b0125","article-title":"E pluribus unum: prospective acceptability benchmarking from the Contouring Collaborative for Consensus in Radiation Oncology crowdsourced initiative for multiobserver segmentation","volume":"10","author":"Lin","year":"2023","journal-title":"J Med Imaging (Bellingham)"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41597-023-02062-w","article-title":"Large scale crowdsourced radiotherapy segmentations across a variety of cancer anatomic sites","volume":"10","author":"Wahid","year":"2023","journal-title":"Sci Data"},{"issue":"4","key":"10.1016\/j.ctro.2024.100790_b0135","article-title":"Achieving exceptional cochlea delineation in radiotherapy scans: the impact of optimal window width and level settings","volume":"15","author":"Shanbhag","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2018.05.001","article-title":"Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus","volume":"128","author":"Lambrecht","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2024.100790_b0145","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1111","key":"10.1016\/j.ctro.2024.100790_b0150","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200142","article-title":"A UK wide study of current prostate planning practice","volume":"93","author":"Taylor","year":"2020","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.ctro.2024.100790_b0155","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.meddos.2020.02.005","article-title":"The challenge of planning vertebral body SBRT: Optimizing target volume coverage","volume":"45","author":"Hardcastle","year":"2020","journal-title":"Med Dosim"},{"issue":"4","key":"10.1016\/j.ctro.2024.100790_b0160","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ac6d82","article-title":"The development of a deep reinforcement learning network for dose-volume-constrained treatment planning in prostate cancer intensity modulated radiotherapy","volume":"8","author":"Sprouts","year":"2022","journal-title":"Biomed Phys Eng Express"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T18:45:16Z","timestamp":1737657916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"alternative-id":["S2405630824000673"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100790","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100790"}}